Fingerprint
Dive into the research topics of 'Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita
Research output: Contribution to journal › Article › peer-review
2
Citations
(Scopus)